# High Lp(a) or ApoB: what to do next

About one adult in five has an Lp(a) above the 2026 US guideline’s risk-enhancing threshold, and no drug that lowers it is approved. That makes a high result confusing: a number you cannot change, attached to a risk you can. This page sets out what counts as high Lp(a) or ApoB under each guideline, what the 2026 ACC/AHA guideline recommends, how far each LDL-lowering option lowers LDL in its trials or label, and what the pelacarsen outcome trial reported on November 7, 2026, all checked on November 13, 2026. It ranks no treatment and sells none.

- Canonical: [https://agewell.guide/guides/high-lpa-apob-what-to-do](https://agewell.guide/guides/high-lpa-apob-what-to-do)
- Markdown: [https://agewell.guide/guides/high-lpa-apob-what-to-do.md](https://agewell.guide/guides/high-lpa-apob-what-to-do.md)
- Updated: 2026-11-13
- Verdict: MEDICAL
- Price range: Unscored · treatment via your clinician
- Reading time: 14 min

## Quick answer

No drug that lowers Lp(a) is approved: in the Lp(a)HORIZON trial, published November 7, 2026, pelacarsen cut Lp(a) by about 78%, but major cardiovascular events occurred in 12.3% on the drug and 12.1% on placebo (hazard ratio 1.02). What lowers risk today is controlling everything else earlier and harder. The 2026 ACC/AHA guideline recommends optimal early control of modifiable risk factors for anyone with Lp(a) of 125 nmol/L (50 mg/dL) or more, says a high Lp(a) favors starting or intensifying LDL-lowering treatment, and sets ApoB goals of under 90, 70 or 55 mg/dL depending on risk. Agewell does not score or rank treatments, and this is not medical advice.

## Agewell verdict

Not scored and not ranked. A high Lp(a) or ApoB is a reason to see your clinician about LDL and ApoB goals, to control blood pressure and glucose more tightly, and to have your parents, siblings and children tested. It is not a reason to start niacin or aspirin on your own: neither has a guideline recommendation for high Lp(a).

## What this page is, and what it is not

A high Lp(a) or ApoB result is a medical finding, so this is an informational guide, not a buying guide. We do not score or rank treatments, we name no product to buy, and there are no affiliate links here. Services with licensed clinicians may buy a clearly labeled placement on Agewell’s medical pages; a placement is never a recommendation, never scored and never changes this page. There are none on this page.

What follows is document-verified synthesis of the 2026 ACC/AHA dyslipidemia guideline, European, Canadian and National Lipid Association guidance, FDA documents, trial registries and peer-reviewed trials, read on November 13, 2026. Nothing here is medical advice. Decisions about tests, targets and medication belong with a clinician who knows your history. If you have not been tested yet, start with our test guide.

[Lp(a) and ApoB tests: where to get them and what they cost](https://agewell.guide/guides/apob-lpa-test)

## What counts as a high Lp(a)

The 2026 ACC/AHA guideline treats an Lp(a) of 125 nmol/L (50 mg/dL) or more as a risk-enhancing factor. That level sits at about the 80th percentile, so it applies to about one person in five. Lp(a) is mostly inherited through the LPA gene, more than 90% genetically determined according to the 2025 European update, and the guideline notes levels are highest in people of African ancestry, with South Asian ancestry also named.

Every guideline draws the line in roughly the same place, but they write it in different units, and the pairs do not match.

**Lp(a) thresholds in current guidelines**

| Guideline | Lower risk | Higher risk | Note |
| --- | ---: | ---: | ---: |
| 2026 ACC/AHA (US) | Under 75 nmol/L (30 mg/dL) is the reference group | 125 nmol/L (50 mg/dL) or more is risk-enhancing | Measure at least once in all adults |
| National Lipid Association, 2024 (US) | Under 75 nmol/L (30 mg/dL); 75 to 125 nmol/L is intermediate | 125 nmol/L (50 mg/dL) or more | Measure at least once in every adult |
| European Atherosclerosis Society, 2022 | “Rule out” under 30 mg/dL (75 nmol/L) | “Rule in” above 50 mg/dL (125 nmol/L) | A grey zone in between |
| ESC/EAS focused update, 2025 | Risk rises slightly from 30 mg/dL (62 nmol/L) | Clinically relevant above 50 mg/dL (105 nmol/L) | Class IIa: a risk-enhancing factor in all adults |
| Canadian Cardiovascular Society, 2021 | Not set | 50 mg/dL (100 nmol/L) or more | Measure once in a lifetime, with the first lipid screen |

The same 50 mg/dL cut-off is paired with 125, 105 and 100 nmol/L, the clearest sign that the two units do not convert exactly. Read your result in the unit your lab reported.

## The risk gradient: higher means more risk, with no cliff

Risk rises continuously with Lp(a), whatever your ancestry. The 2026 guideline gives this gradient against a population median of 20 nmol/L (7 mg/dL), derived from UK Biobank data and “intended as a general guide”. The extra risk multiplies with your other risk factors rather than simply adding to them, which is why most of this page is about those other factors.

**Lp(a) level and relative ASCVD risk, per the 2026 ACC/AHA guideline**

| Lp(a) | Relative ASCVD risk vs the median | Where it sits |
| --- | ---: | ---: |
| Under 75 nmol/L (under 30 mg/dL) | Reference | – |
| 75-124 nmol/L (30-49 mg/dL) | 1.2-fold | – |
| 125 nmol/L (50 mg/dL) | 1.4-fold, about 40% higher | About the 80th percentile |
| 250 nmol/L (100 mg/dL) | 2-fold | About the 95th percentile |
| 350 nmol/L (150 mg/dL) | 3-fold | – |
| 430 nmol/L (180 mg/dL) | 4-fold, similar to heterozygous familial hypercholesterolemia | About the 99th percentile |

2026 ACC/AHA guideline, Table 4, based on UK Biobank data. The guideline adds that a 2-fold risk has been seen at 200 nmol/L in some populations.

## What counts as a high ApoB

ApoB counts particles rather than cholesterol: there is one ApoB molecule on every LDL, VLDL and Lp(a) particle, while LDL cholesterol measures the cholesterol inside LDL particles. When the two disagree, the 2026 guideline says ApoB predicts risk more accurately, and the mismatch is most common in people with heart disease, cardiovascular-kidney-metabolic syndrome, diabetes or triglycerides of 150 mg/dL or more. In the guideline’s words, “LDL-C may appear at goal while apoB remains elevated, masking residual risk.”

The guideline sets ApoB goals by risk, next to LDL cholesterol goals of under 100, 70 or 55 mg/dL (non-HDL cholesterol under 130, 100 or 85 mg/dL) at borderline or intermediate, high and very high risk. European and Canadian guidance set their own numbers, shown below. Canada also recommends ApoB or non-HDL cholesterol instead of LDL as the main screening measure when triglycerides are above 1.5 mmol/L.

**ApoB goals and thresholds by guideline**

| ApoB | Guideline | Who it applies to |
| --- | ---: | ---: |
| Under 90 mg/dL | 2026 ACC/AHA goal | Primary prevention with a PREVENT-ASCVD risk under 10% and triglycerides of 150-499 mg/dL; diabetes without ASCVD risk factors or diabetes-specific risk modifiers |
| Under 70 mg/dL | 2026 ACC/AHA goal | PREVENT-ASCVD risk of 10% or more with triglycerides of 150-499 mg/dL; diabetes with risk factors; high triglycerides with clinical ASCVD not at very high risk, or at age 40-75 with at least one risk factor |
| Under 55 mg/dL | 2026 ACC/AHA goal | Clinical ASCVD at very high risk, including with high triglycerides; to consider with a coronary calcium score of 300 or more, or ASCVD not at very high risk |
| 140 mg/dL or more | 2026 ACC/AHA definition | Severe hypercholesterolemia, as is an LDL-C of 190 mg/dL or more |
| Under 65, 80 or 100 mg/dL | ESC/EAS 2019 secondary goals | Very high, high and moderate risk |
| 105 mg/dL (1.05 g/L) or more | Canadian Cardiovascular Society 2021 | A reason to start a statin at intermediate risk, as is LDL-C of 3.5 mmol/L or more |
| 70 mg/dL (0.7 g/L) or more on treatment | Canadian Cardiovascular Society 2021 | A reason to intensify treatment in secondary prevention, as is LDL-C of 1.8 mmol/L or more |

US goals from the 2026 ACC/AHA guideline’s Figure 1; European and Canadian figures from their own guidelines. PREVENT-ASCVD is the risk calculator the 2026 guideline uses.

## What the 2026 ACC/AHA guideline recommends, in its own words

The 2026 ACC/AHA multisociety Guideline on the Management of Dyslipidemia, published March 13, 2026, replaced the 2018 cholesterol guideline. These are its recommendations that bear on a high Lp(a) or ApoB. Class 1 is worded “is recommended”, Class 2a “is reasonable” and Class 2b “may be reasonable”.

**The 2026 ACC/AHA recommendations on Lp(a) and ApoB, quoted**

| Recommendation (quoted) | Class and evidence level | What it means in practice |
| --- | ---: | ---: |
| “In all adults, measurement of Lp(a) concentration is recommended at least once for ASCVD risk assessment.” | Class 1, B-NR (new) | One Lp(a) test in adulthood is standard care, not an extra |
| “In individuals with FH, premature ASCVD, or high Lp(a), cascade testing of first-degree family members for high Lp(a) concentration is recommended to identify those at increased ASCVD risk.” | Class 1, B-NR | A high result is a reason to test parents, siblings and children |
| “In all individuals with elevated Lp(a) (≥125 nmol/L or ≥50 mg/dL), optimal early control of modifiable cardiovascular risk factors is recommended to reduce ASCVD risk.” | Class 1, B-NR | More intensive control of lipids, blood pressure and glucose, started earlier |
| “In individuals with clinical ASCVD and elevated Lp(a) who have not achieved LDL-C and non-HDL-C treatment goals on maximally tolerated statin therapy, the addition of a PCSK9 mAb with proven cardiovascular benefit is recommended to achieve treatment goals and reduce ASCVD risk.” | Class 1, B-R | With heart disease and a high Lp(a), a PCSK9 antibody is the next step when a statin is not enough |
| “In adults on LLT, particularly those with ASCVD, CKM syndrome, type 2 diabetes, and/or elevated TG, measurement of apoB is reasonable to guide decisions regarding further therapeutic intensification once LDL-C and/or non-HDL-C goals are achieved.” | Class 2a, B-NR | Once you reach your LDL goal on treatment, ApoB can show whether to step up |
| “In adults not on LLT, measurement of apoB may be reasonable to enhance ASCVD risk assessment, guide decisions about initiation of LLT, and characterize inherited lipid disorders.” | Class 2b, B-NR | Before treatment, ApoB is an optional extra input |

Quoted from the guideline’s recommendation tables (Sections 3.3, 3.4 and 4.2.10). LLT means lipid-lowering therapy, TG triglycerides, CKM cardiovascular-kidney-metabolic, FH familial hypercholesterolemia, mAb monoclonal antibody, ASCVD atherosclerotic cardiovascular disease.

## What lowers risk today: LDL and ApoB, not Lp(a) itself

Two lines from the guideline’s supporting text carry the practical message: “An elevated Lp(a) favors initiating or intensifying LLT,” and the relative risk from Lp(a) “is multiplicative with other risk factors.” A high Lp(a) does not change what works. It changes how early and how hard it is worth doing.

No Lp(a)-lowering drug is approved, and PCSK9 inhibitors “are not currently FDA-approved for Lp(a) lowering”. So the evidence-backed plan is to lower what can be lowered. Lowering LDL cholesterol cuts heart attacks and strokes in proportion to how far it falls: the Cholesterol Treatment Trialists’ 2010 meta-analysis of about 170,000 people in 26 trials found 22% fewer major vascular events, and 10% lower all-cause mortality, for each 1 mmol/L (38.7 mg/dL) of LDL lowering.

That benefit holds with a high Lp(a). In the JUPITER trial, a high-intensity statin cut risk by about 30% to 40% in people with elevated Lp(a), according to the 2026 guideline, even though statins do not lower Lp(a) and may raise it slightly, by a mean 1.1 mg/dL against placebo, which the guideline says “would not justify discontinuing the statin.” PCSK9 inhibitors lower Lp(a) by about 15% to 30% on top of their LDL effect. In the FOURIER trial, evolocumab lowered Lp(a) by a median 26.9% at 48 weeks, and its relative benefit was 23% in people with Lp(a) above the median against 7% below it (P for interaction 0.07): a signal, not proof.

Lifestyle barely moves Lp(a), but it still moves the risk. Among people with elevated Lp(a), the guideline cites observational data linking Life’s Essential 8-type habits with 67% lower ASCVD risk.

## How much each LDL-lowering option lowers LDL

This is our own table, built from the guideline’s class ranges, FDA labeling and each drug’s main trial. It shows the size of the LDL effect, not which option suits you: that depends on your risk, your other conditions, side effects, cost and coverage, which is a conversation for your clinician. The numbers come from different kinds of measurement and are not head to head, so read them as rough sizes.

**How much LDL cholesterol each option lowers, from guidelines, labels and trials (checked November 13, 2026)**

| Option | LDL-C lowering | How it was measured | Source |
| --- | ---: | ---: | ---: |
| High-intensity statin | 50% or more | Guideline definition of the intensity class | 2026 ACC/AHA guideline |
| Moderate-intensity statin | 30% to 49% | Guideline definition of the intensity class | 2026 ACC/AHA guideline, Table 6 |
| Ezetimibe alone | About 18% | Guideline summary of trials | 2026 ACC/AHA guideline, Table 5 |
| Ezetimibe added to a statin | About 25% more | Incremental reduction, guideline summary | 2026 ACC/AHA guideline, Table 5 |
| Bempedoic acid alone | 21% to 24% | In people with statin-attributed side effects, guideline summary | 2026 ACC/AHA guideline, Table 5 |
| Bempedoic acid added to a statin | 17% to 18% | Guideline summary | 2026 ACC/AHA guideline, Table 5 |
| Bempedoic acid + ezetimibe (Nexlizet) | 38% | Versus placebo at 12 weeks, on top of maximally tolerated statin | Ballantyne et al., European Journal of Preventive Cardiology 2020 |
| Inclisiran | About 50% (49.9% and 52.3%) | Versus placebo at day 510 in ORION-11 and ORION-10 | Ray et al., NEJM 2020 |
| PCSK9 antibodies as a class | 45% to 64% | Guideline summary of trials | 2026 ACC/AHA guideline, Table 5 |
| Alirocumab (Praluent) | 43% to 58% | Versus placebo at week 24 across the label’s main trials; 36% in the HIGH FH trial | FDA label |
| Evolocumab | 59% | Versus placebo at 48 weeks in FOURIER, from a median 92 to 30 mg/dL | Sabatine et al., NEJM 2017 |
| Enlicitide (Lipfendra), oral PCSK9 inhibitor | 56% to 59% | Versus placebo at week 24 in CORALreef Lipids and CORALreef HeFH; FDA-approved July 2026 | Navar et al., NEJM 2026; Merck; FDA |
| Lerodalcibep (Lerochol), monthly injection | About 56% | Versus placebo at week 52 in LIBerate-HR; US approval December 2025 | Klug et al., JAMA Cardiology 2024; Drugs 2026 |
| Portfolio diet | 13% to 29% | 28.6% when all food was provided for one month (16 people); 13.1% to 13.8% over six months on people’s own, against 3.0% on a control diet (351 people) | Jenkins et al., JAMA 2003 and 2011 |
| Plant sterols or stanols, 2 g a day | 8% to 10% | European Atherosclerosis Society consensus | Gylling et al., Atherosclerosis 2014 |

The trial figures (Nexlizet, inclisiran, alirocumab, evolocumab, enlicitide, lerodalcibep) are placebo-adjusted differences; the diet and sterol figures are changes from baseline; the statin, ezetimibe, bempedoic acid and PCSK9-class figures are the guideline’s ranges. In the enlicitide trials ApoB fell 50% and 48%. Merck’s approval announcement says it is not yet known whether Lipfendra reduces cardiovascular events; its outcome trial has enrolled more than 14,500 people. Agewell names these treatments to describe the evidence, not to recommend one; none is sold or linked here.

## Pelacarsen: what the Lp(a)HORIZON trial found

Pelacarsen is an antisense drug that lowers Lp(a). Lp(a)HORIZON randomized 8,350 people aged 18 to 80 with established cardiovascular disease (a prior heart attack, ischemic stroke or symptomatic peripheral artery disease) and an Lp(a) of at least 70 mg/dL, at 797 sites in 42 countries, to a monthly 80 mg injection of pelacarsen or a placebo. Their median Lp(a) was 236 nmol/L. They were already well treated: median LDL cholesterol was about 65 mg/dL and about 77% to 78% took a high-intensity statin, according to Cleveland Clinic, the study chair’s institution. Results were presented at the American Heart Association’s Scientific Sessions and published in NEJM on November 7, 2026.

The drug did what it was built to do. At 12 months Lp(a) was 64.4 nmol/L on pelacarsen against 233.4 on placebo, a 78.4% fall against 3.2%. It did not prevent events. Over a median 4.7 years, the primary endpoint (cardiovascular death, heart attack, stroke or urgent coronary revascularization) occurred in 511 people (12.3%) on pelacarsen and 503 (12.1%) on placebo: hazard ratio 1.02, 95% confidence interval 0.90 to 1.15, P = 0.76. In the prespecified group with Lp(a) of 90 mg/dL or more, it was 12.3% in both arms (hazard ratio 1.00). Secondary, on-treatment and subgroup analyses were neutral too.

Serious adverse events were 37.3% on pelacarsen and 41.1% on placebo, but 19 people on the drug had adjudicated anaphylaxis against none on placebo, and flu-like symptoms, injection-site reactions and hypersensitivity reactions were more common. Novartis announced on September 4, 2026 that the trial had missed its primary endpoint, and its October 27 results presentation lists the US submission as “Will not be submitted”.

What it means for you. The investigators called the result neutral across every analysis and were careful about its limits: one trial does not prove that lowering Lp(a) can never help, this one enrolled only people who already had heart disease and intensive treatment, newer siRNA drugs lower Lp(a) further and may be better tolerated, and lifelong lowering may be what it takes. They also said Lp(a) remains a causal risk factor, that measuring it is still worthwhile, and that the trial shows how much lowering LDL still matters. For now, a high Lp(a) is managed through the other risk factors, as the guideline already recommends.

## The Lp(a) drugs still in outcome trials

Three more Lp(a)-lowering drugs are in large outcome trials. None has reported. The dates below are the registry’s own estimates of primary completion, not approval dates, and after pelacarsen a positive result cannot be assumed. Muvalaplin’s trial was still recruiting when we checked.

**Lp(a)-lowering drugs in cardiovascular outcome trials (checked November 13, 2026)**

| Drug (company) | Trial | Who it enrolls | Status on ClinicalTrials.gov | Estimated primary completion |
| --- | ---: | ---: | ---: | ---: |
| Olpasiran (Amgen), siRNA | OCEAN(a)-Outcomes, NCT05581303 | Established ASCVD and Lp(a) of 200 nmol/L or more; 7,297 enrolled | Active, not recruiting (record updated October 27, 2026) | March 31, 2028 |
| Lepodisiran (Lilly), siRNA | ACCLAIM-Lp(a), NCT06292013 | Lp(a) of 175 nmol/L or more; about 17,300 planned | Active, not recruiting (record updated October 8, 2026) | March 2029 |
| Muvalaplin (Lilly), oral | MOVE-Lp(a), NCT07157774 | Lp(a) of 175 nmol/L or more; about 10,450 planned | Recruiting, started September 2, 2025 | March 2031 |
| Zerlasiran (Silence Therapeutics), siRNA | No outcome trial registered | – | Merck KGaA, Darmstadt agreed on October 19, 2026 to acquire Silence; its November 12 results gave no Phase 3 plan | – |

From ClinicalTrials.gov records and company filings checked November 13, 2026. “Planned” enrollment is the registry’s estimate. Novartis lists its own Lp(a) siRNA, DII235, as under assessment.

## Apheresis: a narrow option

Lipoprotein apheresis has an FDA indication that names Lp(a), and it is narrow. In 2020 FDA added this group to the indication for the Kaneka LIPOSORBER LA-15 system: “Functional Hypercholesterolemic Heterozygotes with LDL-C >= 100 mg/dl and lipoprotein(a) [Lp(a)] >= 60 mg/dL, and either documented coronary artery disease or documented peripheral artery disease.”

Published summaries of that indication differ in their details, so we quote FDA’s own wording and give no nmol/L equivalent. If you think you might meet it, ask your clinician about a referral to a lipid specialist.

## Aspirin and niacin

Aspirin: no recommendation for high Lp(a). The 2026 guideline notes that post hoc analyses of two primary prevention trials found fewer events with aspirin in people with high Lp(a), “but prospective trials in individuals with elevated Lp(a) are needed.” The European Atherosclerosis Society’s 2022 consensus says current data “do not support targeting aspirin use based on Lp(a) levels.” Whether aspirin is right for you is a question for your clinician.

Niacin: not recommended. It lowers Lp(a), as the Canadian guideline notes, but the European consensus says it “is not recommended given the lack of clinical benefit in two outcomes studies,” and the 2026 US guideline says randomized trials do not support adding niacin or fibrates to a statin.

## Test your family

Lp(a) is inherited in an autosomal codominant pattern, so a high result says something about your relatives. The 2026 guideline recommends cascade testing, measuring Lp(a) in first-degree relatives (parents, siblings and children) of anyone with high Lp(a), familial hypercholesterolemia or premature ASCVD. The National Lipid Association and European guidance say the same. Levels can rise until adulthood, so the European consensus notes a young person may need more than one test.

[Where to get an Lp(a) test, from $27.74](https://agewell.guide/guides/apob-lpa-test)

## When to see whom, and what to ask

Start with your primary care clinician, who can put your Lp(a) and ApoB next to your blood pressure, glucose, family history and a risk estimate such as PREVENT, then agree LDL and ApoB goals with you. The guideline says “Patient referral to a specialist could be considered in select cases.” Situations covered on this page that may count: heart disease with LDL above goal on the highest statin dose you tolerate, an LDL of 190 mg/dL or more or an ApoB of 140 mg/dL or more, a profile that might meet the FDA apheresis criteria, or interest in a trial. The guideline does not advise genetic testing for Lp(a), because the measured level is enough.

Bring your lab report, with the assay and unit, and these questions.

**Questions to take to your clinician about a high Lp(a) or ApoB**

| Ask | Why it matters |
| --- | ---: |
| Which assay and unit was my Lp(a) measured in? | mg/dL and nmol/L do not convert exactly, and the guideline asks labs to report both the assay and the unit |
| Given my Lp(a), should we start or step up cholesterol treatment? | The 2026 guideline says an elevated Lp(a) favors starting or intensifying lipid-lowering therapy |
| What are my LDL and ApoB goals, and when do we recheck? | The guideline sets goals by risk, from an ApoB under 90 mg/dL down to under 55 |
| I have heart disease and am not at goal on a statin: is a PCSK9 antibody next? | A Class 1 recommendation for people with ASCVD and elevated Lp(a) |
| Should my parents, siblings and children be tested? | Cascade testing is a Class 1 recommendation |
| Could I qualify for apheresis or an Lp(a) trial? | Apheresis has narrow FDA criteria; one outcome trial was still recruiting in November 2026 |

Built from the guidelines and FDA documents cited below. Not a substitute for your own clinician’s advice.

## FAQ

### How do you lower Lp(a)?

For now, mostly you cannot. Lp(a) is more than 90% genetically determined, barely moves with lifestyle, and no drug is approved to lower it. PCSK9 inhibitors lower it by about 15% to 30% but are not FDA-approved for that purpose, and apheresis is reserved for a narrow group. The 2026 ACC/AHA guideline’s advice for a high Lp(a) is optimal early control of everything else, starting with LDL cholesterol. This is not medical advice.

### What Lp(a) level is considered high?

Under the 2026 ACC/AHA guideline, 125 nmol/L (50 mg/dL) or more is high and counts as a risk-enhancing factor; about one adult in five is above it, with about 40% higher risk than at the median. At 430 nmol/L (180 mg/dL), around the 99th percentile, risk is about four times higher, similar to heterozygous familial hypercholesterolemia. The 2025 European update and Canada’s guideline pair 50 mg/dL with 105 and 100 nmol/L.

### Did pelacarsen work?

It lowered Lp(a) but did not prevent heart attacks or strokes. In Lp(a)HORIZON, published in NEJM on November 7, 2026, pelacarsen cut Lp(a) by about 78%, but major cardiovascular events occurred in 12.3% on the drug and 12.1% on placebo over a median 4.7 years (hazard ratio 1.02). Novartis lists the US submission as “Will not be submitted”.

### When will an Lp(a)-lowering drug be available?

Not before the outcome trials report, and none has a confirmed date. ClinicalTrials.gov estimates primary completion in March 2028 for olpasiran (OCEAN(a)-Outcomes), March 2029 for lepodisiran (ACCLAIM-Lp(a)) and March 2031 for oral muvalaplin (MOVE-Lp(a)). After pelacarsen, a positive result cannot be assumed.

### What is a good ApoB level?

It depends on your risk. The 2026 ACC/AHA guideline sets ApoB goals of under 90 mg/dL in lower-risk primary prevention with triglycerides of 150 to 499 mg/dL, under 70 mg/dL at higher risk or with diabetes and risk factors, and under 55 mg/dL for clinical ASCVD at very high risk. The 2019 European goals are under 100, 80 and 65 mg/dL. Agree your own goal with your clinician.

### Does a statin lower Lp(a)?

No. The 2026 ACC/AHA guideline says statins do not lower Lp(a) and may raise it slightly, by a mean 1.1 mg/dL against placebo, which it says would not justify stopping the statin. Statins still lower risk with a high Lp(a): in JUPITER, a high-intensity statin cut risk by about 30% to 40% in that group. Do not stop a prescribed statin without your clinician.

### Should my family get tested for high Lp(a)?

Yes, if you have high Lp(a), familial hypercholesterolemia or early heart disease. The 2026 ACC/AHA guideline recommends testing parents, siblings and children for Lp(a) in that case (Class 1). Our test guide lists where to get it and what it costs, from $27.74.

### Should I take niacin or aspirin for high Lp(a)?

Not on your own. Niacin lowers Lp(a) but is not recommended, because two outcome trials showed no clinical benefit. For aspirin, post hoc analyses suggest benefit in people with high Lp(a), but no guideline recommends it on that basis and prospective trials are needed. Ask your clinician.

## Sources

- [ACC/AHA (Circulation, 2026): 2026 Guideline on the Management of Dyslipidemia: Lp(a) and ApoB recommendations, Table 4 risk gradient, ApoB and LDL-C goals, LDL-lowering ranges (Tables 5 and 6), statins and Lp(a), JUPITER, Life’s Essential 8, aspirin, niacin, cascade testing, referral](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001423)
- [ACC/AHA (JACC, 2026): The same guideline in JACC, 2026;87(19):2624-2757](https://www.jacc.org/doi/10.1016/j.jacc.2025.11.016)
- [AHA newsroom: ACC/AHA issue updated guideline for managing lipids and cholesterol (March 13, 2026)](https://newsroom.heart.org/news/accaha-issue-updated-guideline-for-managing-lipids-cholesterol)
- [National Lipid Association (Journal of Clinical Lipidology, 2024): Focused update on Lp(a): measure once in every adult, 75 and 125 nmol/L risk categories, cascade screening](https://doi.org/10.1016/j.jacl.2024.03.001)
- [European Atherosclerosis Society (European Heart Journal, 2022): Lp(a) consensus statement: rule-out and rule-in thresholds, no conversion factor, cascade testing, aspirin and niacin](https://pmc.ncbi.nlm.nih.gov/articles/PMC9639807/)
- [ESC/EAS (European Heart Journal, 2025): 2025 focused update: Lp(a) more than 90% genetic, risk-enhancing above 50 mg/dL (105 nmol/L), Class IIa](https://academic.oup.com/eurheartj/article/46/42/4359/8234482)
- [ESC/EAS (European Heart Journal, 2019): 2019 dyslipidaemia guidelines: ApoB goals of under 65, 80 and 100 mg/dL](https://academic.oup.com/eurheartj/article/41/1/111/5556353)
- [Canadian Cardiovascular Society (2021): Dyslipidemia guideline: Lp(a) once in a lifetime, 50 mg/dL (100 nmol/L), ApoB thresholds, ApoB or non-HDL-C when triglycerides are above 1.5 mmol/L, niacin](https://doi.org/10.1016/j.cjca.2021.03.016)
- [Cho et al., NEJM (2026): Lp(a)HORIZON: pelacarsen and cardiovascular outcomes, 8,350 randomized, Lp(a) at 12 months, MACE 12.3% vs 12.1%, HR 1.02, serious adverse events](https://www.nejm.org/doi/full/10.1056/NEJMoa2610159)
- [AHA newsroom: Lp(a)HORIZON presented November 7, 2026: neutral outcomes, anaphylaxis, investigators’ reading](https://newsroom.heart.org/news/lp-a-horizon-trial-lp-a-fell-by-78-but-cardiovascular-outcomes-unexpectedly-neutral)
- [Cleveland Clinic newsroom: Lp(a) fell 78.4% vs 3.2% at 12 months; neutral results after nearly five years (November 7, 2026)](https://newsroom.clevelandclinic.org/2026/11/07/cleveland-clinic-trial-shows-novel-lipoproteina-drug-did-not-reduce-major-cardiovascular-events-after-nearly-5-years)
- [Cleveland Clinic Consult QD: Baseline LDL-C about 65 mg/dL and high-intensity statin use in Lp(a)HORIZON (November 7, 2026)](https://consultqd.clevelandclinic.org/lipoproteina-reduction-with-pelacarsen-has-no-impact-on-cardiac-events)
- [ClinicalTrials.gov: Lp(a)HORIZON, NCT04023552: completed](https://clinicaltrials.gov/study/NCT04023552)
- [Novartis: Lp(a)HORIZON topline: primary endpoint not met (September 4, 2026)](https://www.novartis.com/news/media-releases/novartis-announces-lpahorizon-phase-iii-topline-results-pelacarsen-patients-elevated-lpa-and-established-cardiovascular-disease-cvd)
- [Novartis: Q3 2026 investor presentation (October 27, 2026): pelacarsen US submission “Will not be submitted”; DII235 under assessment](https://www.novartis.com/sites/novartis_com/files/q3-2026-investor-presentation.pdf)
- [ClinicalTrials.gov: OCEAN(a)-Outcomes, olpasiran, NCT05581303: 7,297 enrolled, active, primary completion estimated March 31, 2028, checked 2026-11-13](https://clinicaltrials.gov/study/NCT05581303)
- [ClinicalTrials.gov: ACCLAIM-Lp(a), lepodisiran, NCT06292013: about 17,300, active, estimated March 2029, checked 2026-11-13](https://clinicaltrials.gov/study/NCT06292013)
- [ClinicalTrials.gov: MOVE-Lp(a), muvalaplin, NCT07157774: about 10,450, recruiting, estimated March 2031, checked 2026-11-13](https://clinicaltrials.gov/study/NCT07157774)
- [Silence Therapeutics (SEC filing): Silence Therapeutics filing: agreed acquisition by Merck KGaA, Darmstadt; no zerlasiran Phase 3 plan in its November 12, 2026 update](https://www.sec.gov/Archives/edgar/data/0001479615/000119312526457060/d101909dex991.htm)
- [O’Donoghue et al., Circulation (2019): FOURIER: evolocumab lowered Lp(a) by a median 26.9%; relative benefit 23% vs 7% above and below median Lp(a)](https://pubmed.ncbi.nlm.nih.gov/30586750/)
- [FDA: PMA supplement P910018/S027 (April 21, 2020): Kaneka LIPOSORBER LA-15 indication for Lp(a) of 60 mg/dL or more](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P910018S027)
- [Cholesterol Treatment Trialists’ Collaboration, Lancet (2010): 26 trials, about 170,000 people: rate ratio 0.78 per 1 mmol/L LDL-C reduction; all-cause mortality 10% lower](https://doi.org/10.1016/S0140-6736(10)61350-5)
- [Ballantyne et al., European Journal of Preventive Cardiology (2020): Bempedoic acid plus ezetimibe fixed-dose combination: 38.0% placebo-corrected LDL-C reduction at 12 weeks](https://doi.org/10.1177/2047487319864671)
- [Ray et al., NEJM (2020): ORION-10 and ORION-11: inclisiran lowered LDL-C by 52.3% and 49.9% vs placebo at day 510](https://doi.org/10.1056/NEJMoa1912387)
- [FDA label (DailyMed): Praluent (alirocumab) prescribing information, revised October 2025: placebo-adjusted LDL-C reductions of 43% to 58% at week 24, 36% in HIGH FH](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bcfbac2-e8ac-4569-8edc-bcde3b1fd172)
- [Sabatine et al., NEJM (2017): FOURIER: evolocumab lowered LDL-C by 59% vs placebo at 48 weeks, from a median 92 to 30 mg/dL](https://doi.org/10.1056/NEJMoa1615664)
- [Navar et al., NEJM (2026): CORALreef Lipids: enlicitide lowered LDL-C by 55.8 percentage points vs placebo at week 24](https://doi.org/10.1056/NEJMoa2511002)
- [Merck: Lipfendra (enlicitide) FDA approval (July 16, 2026): 56% and 59% placebo-adjusted LDL-C reductions, ApoB down 50% and 48%, outcome trial ongoing with more than 14,500 enrolled](https://www.merck.com/news/mercks-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibitor-approved-by-the-u-s-fda-to-reduce-ldl-c-in-adults-with-hypercholesterolemia/)
- [FDA: FDA approves first oral PCSK9 inhibitor to lower LDL cholesterol (July 2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol)
- [Klug et al., JAMA Cardiology (2024): LIBerate-HR: lerodalcibep lowered LDL-C by 56.2% vs placebo at week 52](https://doi.org/10.1001/jamacardio.2024.1659)
- [Zhuang-Yan and Blair, Drugs (2026): Lerodalcibep: first US approval as Lerochol, once-monthly injection (December 2025)](https://doi.org/10.1007/s40265-026-02317-x)
- [National Lipid Association: LIB Therapeutics release: FDA approves Lerochol (lerodalcibep-liga) for adults with elevated LDL cholesterol (December 15, 2025)](https://www.lipid.org/resource/us-food-and-drug-administration-approves-lib-therapeutics-lerochol-lerodalcibep-liga-for-adults-with-elevated-ldl-cholesterol/)
- [Jenkins et al., JAMA (2003): Portfolio diet: 28.6% LDL-C reduction in one month with all food provided (16 people)](https://doi.org/10.1001/jama.290.4.502)
- [Jenkins et al., JAMA (2011): Portfolio diet over six months, free-living: 13.8% and 13.1% vs 3.0% on the control diet (351 people)](https://doi.org/10.1001/jama.2011.1202)
- [European Atherosclerosis Society consensus, Atherosclerosis (2014): Plant sterols or stanols at 2 g a day lower LDL-C by 8% to 10%](https://doi.org/10.1016/j.atherosclerosis.2013.11.043)

## Next

- [Lp(a) and ApoB tests: where to get them and what they cost](https://agewell.guide/guides/apob-lpa-test)
- [Best blood test memberships, compared per draw](https://agewell.guide/guides/best-blood-test-memberships)
- [The Baseline Month](https://agewell.guide/guides/baseline-month)
- [The Longevity Readiness Check](https://agewell.guide/readiness)
